The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1270 articles
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
The rise of GLP-1 medications like Ozempic and Wegovy is transforming health and lifestyles, but it's also leading to an unexpected side effect: 'Ozempic breath'. This phenomenon is creating a surprising boon for confectionary companies, particularly Hershey, as consumers seek relief. Learn more about this fascinating intersection of pharmaceuticals and consumer goods.
The rise of GLP-1 medications like Ozempic and Mounjaro has coincided with a notable shift in aesthetic preferences, particularly concerning breast size. This article delves into the potential links, societal pressures, and practical considerations for women navigating these changes.
New research from the University of St Andrews offers a glimmer of hope for individuals using GLP-1 medications who become pregnant. This comprehensive review of nearly 50,000 pregnancies suggests a potentially lower risk of adverse outcomes than previously feared, though experts emphasize caution.
Eli Lilly's first quarter of 2026 saw record-breaking performance, largely propelled by the immense demand for its GLP-1 based therapies, Mounjaro and Zepbound. The pharmaceutical giant not only surpassed financial expectations but also significantly raised its full-year outlook, signaling continued growth and innovation in the metabolic disease space.
A new daily pill, Orforglipron, is emerging as a significant contender in the weight loss and diabetes management space, offering a potential oral alternative to injectable GLP-1 medications. This article delves into its mechanisms, trial results, and what it means for the future of treatment.
Losing weight with GLP-1 medications like semaglutide and tirzepatide is a significant achievement, but maintaining that loss after stopping treatment presents a major challenge. A new experimental procedure, duodenal mucosal resurfacing (DMR), is showing remarkable potential in helping individuals keep the pounds off.
A comprehensive analysis of recent data shows that stopping GLP-1 medications like Ozempic and Wegovy often leads to weight regain and a return of cardiometabolic risk markers. Here is what you need to know about long-term outcomes and maintenance strategies.
Dr. Reddy's Laboratories has achieved a significant milestone by becoming the first company to receive market authorization from Health Canada for its generic semaglutide injection. This development promises to increase access to a crucial treatment option for Canadians.
